LO1 : Safety of ombitasvir/paritaprevir/ritonavir plus dasabuvir for treating HCV GT1 infection in patients with severe renal impairment or end-stage renal disease: The RUBY-I study

Journal of Hepatology ◽

10.1016/s0168-8278(15)30147-1 ◽

2015 ◽

Vol 62 ◽

pp. S257 ◽

Cited By ~ 51

Author(s):

P.J. Pockros ◽

K.R. Reddy ◽

P.S. Mantry ◽

E. Cohen ◽

M. Bennett ◽

...

Keyword(s):

Renal Impairment ◽

Renal Disease ◽

End Stage Renal Disease ◽

Severe Renal Impairment ◽

Stage Renal Disease ◽

End Stage

Download Full-text

Serum inhibitory and bactericidal activity of telavancin in non-infected subjects with severe renal impairment or end-stage renal disease

Diagnostic Microbiology and Infectious Disease ◽

10.1016/j.diagmicrobio.2014.09.002 ◽

2014 ◽

Vol 80 (4) ◽

pp. 327-329 ◽

Cited By ~ 8

Author(s):

Steven L. Barriere ◽

David J. Farrell ◽

Paul R. Rhomberg ◽

Ronald N. Jones

Keyword(s):

Renal Impairment ◽

Renal Disease ◽

Bactericidal Activity ◽

End Stage Renal Disease ◽

Severe Renal Impairment ◽

Stage Renal Disease ◽

End Stage

Download Full-text

The pharmacokinetics (PK) of aprepitant are not affected in patients with end-stage renal disease (ESRD) or severe renal impairment

Inpharma Weekly ◽

10.2165/00128413-200514940-00044 ◽

2005 ◽

Vol &NA; (1494) ◽

pp. 19

Author(s):

&NA;

Keyword(s):

Renal Impairment ◽

Renal Disease ◽

End Stage Renal Disease ◽

Severe Renal Impairment ◽

Stage Renal Disease ◽

End Stage

Download Full-text

Ombitasvir/Paritaprevir/Ritonavir plus Dasabuvir are Safety and Eficacy for Treating HCV GT1 and 4 Infection in Patients with Severe Renal Impairment or End-Stage Renal Disease: A Mulcicenter Experience

Journal of Hepatology ◽

10.1016/s0168-8278(16)01588-9 ◽

2016 ◽

Vol 64 (2) ◽

pp. S813 ◽

Cited By ~ 1

Author(s):

R.M. Gómez ◽

D. Rincón ◽

E. Hernández ◽

A. Ahumada ◽

M.D. Pérez Valderas ◽

...

Keyword(s):

Renal Impairment ◽

Renal Disease ◽

End Stage Renal Disease ◽

Severe Renal Impairment ◽

Stage Renal Disease ◽

End Stage

Download Full-text

A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end‐stage renal disease requiring haemodialysis

British Journal of Haematology ◽

10.1111/bjh.14125 ◽

2016 ◽

Vol 174 (5) ◽

pp. 748-759 ◽

Cited By ~ 28

Author(s):

Neeraj Gupta ◽

Michael J. Hanley ◽

R. Donald Harvey ◽

Ashraf Badros ◽

Brea Lipe ◽

...

Keyword(s):

Multiple Myeloma ◽

Renal Impairment ◽

Renal Disease ◽

End Stage Renal Disease ◽

Severe Renal Impairment ◽

Phase 1 ◽

Stage Renal Disease ◽

End Stage

Download Full-text

Pharmacokinetics of serelaxin in patients with severe renal impairment or end‐stage renal disease requiring hemodialysis: A single‐dose, open‐label, parallel‐group study

The Journal of Clinical Pharmacology ◽

10.1002/jcph.607 ◽

2015 ◽

Vol 56 (4) ◽

pp. 474-483 ◽

Cited By ~ 14

Author(s):

Marion Dahlke ◽

Atef Halabi ◽

Jasna Canadi ◽

Chiaki Tsubouchi ◽

Surendra Machineni ◽

...

Keyword(s):

Single Dose ◽

Renal Impairment ◽

Renal Disease ◽

End Stage Renal Disease ◽

Severe Renal Impairment ◽

Open Label ◽

Parallel Group Study ◽

Parallel Group ◽

Stage Renal Disease ◽

End Stage

Download Full-text

Low-Dose Sofosbuvir Is Safe and Effective in Treating Chronic Hepatitis C in Patients with Severe Renal Impairment or End-Stage Renal Disease

Digestive Diseases and Sciences ◽

10.1007/s10620-018-4979-6 ◽

2018 ◽

Vol 63 (5) ◽

pp. 1334-1340 ◽

Cited By ~ 20

Author(s):

Sunil Taneja ◽

Ajay Duseja ◽

Arka De ◽

Manu Mehta ◽

Raja Ramachandran ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C ◽

Renal Impairment ◽

Renal Disease ◽

Chronic Hepatitis C ◽

End Stage Renal Disease ◽

Low Dose ◽

Severe Renal Impairment ◽

Stage Renal Disease ◽

End Stage

Download Full-text

IDDF2021-ABS-0078 Switching from tenofovir disoproxil fumarate (TDF) and/or other oral antivirals (OAVS) to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with moderate or severe renal impairment, or with end-stage renal disease (ESRD)

10.1136/gutjnl-2021-iddf.80 ◽

2021 ◽

Author(s):

Harry LA Janssen ◽

Pietro Lampertico ◽

Chien-Hung Chen ◽

Jeong Heo ◽

Claire Fournier ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis B ◽

Renal Impairment ◽

Renal Disease ◽

End Stage Renal Disease ◽

Tenofovir Disoproxil Fumarate ◽

Severe Renal Impairment ◽

Tenofovir Alafenamide ◽

Stage Renal Disease ◽

End Stage

Download Full-text

Pharmacokinetics of elbasvir and grazoprevir in subjects with end-stage renal disease or severe renal impairment

European Journal of Clinical Pharmacology ◽

10.1007/s00228-018-2585-3 ◽

2019 ◽

Vol 75 (5) ◽

pp. 665-675 ◽

Cited By ~ 3

Author(s):

Luzelena Caro ◽

Larissa Wenning ◽

Hwa-Ping Feng ◽

Zifang Guo ◽

Lihong Du ◽

...

Keyword(s):

Renal Impairment ◽

Renal Disease ◽

End Stage Renal Disease ◽

Severe Renal Impairment ◽

Stage Renal Disease ◽

End Stage

Download Full-text

A retrospective observational study on the use of capecitabine in patients with severe renal impairment (GFR <30 mL/min) and end stage renal disease on hemodialysis

Journal of Oncology Pharmacy Practice ◽

10.1177/1078155210390255 ◽

2012 ◽

Vol 18 (1) ◽

pp. 140-147 ◽

Cited By ~ 7

Author(s):

Kenar D Jhaveri ◽

Carlos Flombaum ◽

Manish Shah ◽

Sheron Latcha

Keyword(s):

Renal Impairment ◽

Observational Study ◽

Renal Disease ◽

End Stage Renal Disease ◽

Severe Renal Impairment ◽

Retrospective Observational Study ◽

Stage Renal Disease ◽

End Stage

Download Full-text

Specified Drug-Use Survey of Trelagliptin Tablets "Survey on Long-term Use in Type 2 Diabetes Mellitus Patients With Severe Renal Impairment or End-stage Renal Disease"

Case Medical Research ◽

10.31525/ct1-nct04285983 ◽

2020 ◽

Author(s):

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Renal Impairment ◽

End Stage Renal Disease ◽

Severe Renal Impairment ◽

Stage Renal Disease ◽

End Stage

Download Full-text